{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
acetylcholine
to a specific field?
Status:
US Previously Marketed
First approved in 1951
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Dimethisoquin (also known as Quinisocaine and QUOTANE) is a topical anesthetic used as an antipruritic. It was shown that dimethisoquin inhibits nicotinic acetylcholine receptors (alpha4/beta4 and alpha4/beta2) with the maximum inhibition potency occurring for the α4β4 subtype.
Status:
US Previously Marketed
Source:
HEXAMETHONIUM CHLORIDE HEXAMETHONIUM CHLORIDE by NYSCO
(1961)
Source URL:
First approved in 1951
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Hexamethonium is a nicotinic cholinergic antagonist. It was used to treat hypertension, but has never been approved and was discontinued because of the non-specified treatment. When this drug tried to use in medical study via inhalation, one of the volunteer died, the death has been described as “particularly disturbing ”because it was a healthy volunteer who had no thing to gain by taking part in the study. This volunteer participated in a study designed to provoke a mild asthma attack in order to help doctors discover the reflex that protects the lungs of healthy people against asthma attacks. Hexamethonium is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. Now it is widely used a research tool.
Status:
US Previously Marketed
First approved in 1951
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
US Previously Marketed
Source:
HEXAMETHONIUM CHLORIDE HEXAMETHONIUM CHLORIDE by NYSCO
(1961)
Source URL:
First approved in 1951
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Hexamethonium is a nicotinic cholinergic antagonist. It was used to treat hypertension, but has never been approved and was discontinued because of the non-specified treatment. When this drug tried to use in medical study via inhalation, one of the volunteer died, the death has been described as “particularly disturbing ”because it was a healthy volunteer who had no thing to gain by taking part in the study. This volunteer participated in a study designed to provoke a mild asthma attack in order to help doctors discover the reflex that protects the lungs of healthy people against asthma attacks. Hexamethonium is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. Now it is widely used a research tool.
Status:
US Previously Marketed
Source:
SYNCURINE by GLAXOSMITHKLINE
(1950)
Source URL:
First approved in 1950
Source:
SYNCURINE by GLAXOSMITHKLINE
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Decamethylene disquaternary salts, with a ten-carbon (C10) chain between the quaternary groups, had the most potent curariform action in the series of polymethylene bisquaternaries. Decamethonium was used clinically as a neuromuscular blocking drug for a short time. Decamethonium was different from d-tubocurarine and that it produced a transient augmentation of contraction. C10 produces neuromuscular block by initiating some active response in the endplate or muscle fibre. Unlike d-tubocurare, decamethonium was not reversed by anticholinesterase agents.
Status:
US Previously Marketed
Source:
SYNCURINE by GLAXOSMITHKLINE
(1950)
Source URL:
First approved in 1950
Source:
SYNCURINE by GLAXOSMITHKLINE
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Decamethylene disquaternary salts, with a ten-carbon (C10) chain between the quaternary groups, had the most potent curariform action in the series of polymethylene bisquaternaries. Decamethonium was used clinically as a neuromuscular blocking drug for a short time. Decamethonium was different from d-tubocurarine and that it produced a transient augmentation of contraction. C10 produces neuromuscular block by initiating some active response in the endplate or muscle fibre. Unlike d-tubocurare, decamethonium was not reversed by anticholinesterase agents.
Status:
US Previously Marketed
Source:
SYNCURINE by GLAXOSMITHKLINE
(1950)
Source URL:
First approved in 1950
Source:
SYNCURINE by GLAXOSMITHKLINE
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Decamethylene disquaternary salts, with a ten-carbon (C10) chain between the quaternary groups, had the most potent curariform action in the series of polymethylene bisquaternaries. Decamethonium was used clinically as a neuromuscular blocking drug for a short time. Decamethonium was different from d-tubocurarine and that it produced a transient augmentation of contraction. C10 produces neuromuscular block by initiating some active response in the endplate or muscle fibre. Unlike d-tubocurare, decamethonium was not reversed by anticholinesterase agents.
Status:
First approved in 1949
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Caramiphen is a muscarinic M1 acetylcholine receptor antagonist, which was used for the treatment of Parkinson Disease and cough, but then there using were discontinued. Caramiphen is also used in local anesthesia, and effect could be achieved through the suppression of voltage-gated Na⁺ currents.
Status:
First approved in 1949
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Caramiphen is a muscarinic M1 acetylcholine receptor antagonist, which was used for the treatment of Parkinson Disease and cough, but then there using were discontinued. Caramiphen is also used in local anesthesia, and effect could be achieved through the suppression of voltage-gated Na⁺ currents.
Status:
US Previously Marketed
First approved in 1947
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Tetraethylammonium is an experimental drug with no approved indication or marketed formulation. Tetraethylammonium blocks of apamin-sensitive and insensitive Ca2(+)-activated K+ channels. It is a weak agonist of the nicotinic receptor. Tetraethylammonium produces transient reductions in blood pressure. Tetraethylammonium hydroxide is used as a soluble source of hydroxide ions and in the synthesis of ionic organic compounds.
